Interim Job Aid for Monkeypox (MPV) Post Exposure Prophylaxis (PEP):
Part 1- Product Information

This Job Aid is only for use if the Chicago Department of Public Health has already approved of administering vaccination. For questions about monkeypox (MPV) post exposure prophylaxis administration, please reach out to monkeypoxpep@cityofchicago.org.

Product Information: Jynneos Vaccine
(For further details, please see attached package insert.)

Jynneos is a live, non-replicating vaccine labeled for smallpox and monkeypox virus (MPV).

Indications and eligibility for PEP:

PEP is for individuals who:
- In consultation with the Chicago Department of Public Health, have had a high or intermediate risk exposure to a confirmed case of monkeypox,
- Have had a MPV exposure in the past 14 days.

PEP ++ is for:
- Gay men, bisexual men, and other men who have sex with men, (GBMSM) and trans-persons who are sexually active and have never been infected with MPV.

Preparation and Administration:

Jynneos is a suspension in a 0.5 ml vial.

- The standard regimen (FDA approved) is 0.5 ml subcutaneous administration.
- The alternative regimen (approved for emergency use on 8.9.22) is 0.1 ml intradermal administration. This allows for additional availability of vaccine to a larger population while maintaining similar immunogenicity to the SQ administration. Evidence for ID Administration of Jynneos.
- CDPH supports administration as follows:
  - 0.1 ml intradermal administration (alternative regimen) for adults age 18 and over.
  - 0.5 ml subcutaneous administration (standard regimen) for minors age 17 and younger.
    - When using the standard regimen, there is no lower age limit
- With both routes of administration, CDPH recommends administration of 2 doses, no sooner than 28 days apart for both PEP and PEP ++
- If dose 1 was administered subcutaneously, it is appropriate to administer dose 2 intra-dermally.

**Intradermal Injection Process:** (See video for training.)

- For intradermal injection: use a tuberculin syringe with a 27 or 26 gauge, 1/4 to 1/2” needle with a short bevel. Always use a new, sterile needle and syringe for each injection.
- For subcutaneous injection: use sterile syringe with a 23–25 gauge, 5/8” needle.
- Injection should be administered to the volar (inner arm).
- If swelling occurs from the first to second administration, administer next dose in contralateral arm.
- If the volar forearm is not an option (e.g., heavy scarring, bilateral amputation), the upper back below the scapula may be used.
- If you do not see a wheal form, or have other questions about troubleshooting, please see **Vaccine Administration Errors** for more information.
  - Bavarian Nordic contact information:
    - Email: medical_information_US@bavarian-nordic.com
    - U.S. phone number: 1-844-422-8274
    - U.S. fax number: 1-843-422-8274
Side effects:
- Minimal side effects have been reported, but most commonly include:
  - Injection site pain, redness, and swelling,
  - Muscle pain, headache, fatigue
  - For intradermal injection, higher risk of erythema, induration, itchiness, and pain at injection site, in comparison to SQ administration.
  - Patients with suspected adverse events should visit their healthcare provider, and their symptoms should be reported through VAERS.

Contraindications:
- If the individual has previously had a history of severe allergies, particularly to vaccines, their risk for contracting monkeypox should be evaluated.
- Side effects in individuals living with HIV and severe atopic dermatitis were comparable to those for healthy adults.
- If an individual has a history of keloid formation, it is recommended to administer subcutaneously.

Storage:
Please see updated package insert (attached).
- Jynneos may be stored at 2-8°C for up to 8 weeks. NOTE: This is an update to the original package insert that requires storage at -20°C
- Unpunctured vials may be stored at room temperature for 6 cumulative hours.
- Punctured vials may be stored in the refrigerator for up to 8 hours.

Direct patients to Jynneos Patient Fact Sheet for further Q and A.

For additional information including package inserts and sample standing orders visit:
CDC: Jynneos vaccine
Job Aid for Healthcare Workers Administering MPV Post Exposure Prophylaxis (PEP): Part 2- Reporting

Reporting to CDPH
Prior to receipt of the vaccine, providers will be required to sign and return a “Monkeypox Virus Vaccine Provider Agreement” to CDPH, indicating their willingness to report in ICARE.

Reporting in ICARE

- If you have an HL7, the administration of Jynneos can be entered into ICARE directly from your EMR.
- Alternatively, Jynneos administration can be entered into the “Other” part of ICARE, as seen below:
Reporting Wastage in ICARE:

Click “Add Transaction”

Select a lot number.

From the vaccines tab, click on the lot number you wish to edit.

Select “Wasted”